{"product_id":"myo-ansoff-analysis","title":"(MYO) Myomo, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Myomo, Inc. Ansoff Matrix Analysis summarizes the company’s growth options across market penetration, market development, product development, and diversification and shows how each option applies to Myomo’s assistive robotics business; the page includes a real preview\/sample so you can assess style and substance before buying. Purchase the full version to get the complete, ready-to-use analysis for strategy, research, or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeepen U.S. MyoPro adoption in stroke rehabilitation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 795,000 people in the U.S. have a stroke each year, creating a large pool of arm-rehab patients. MyoPro can target those with weak or paralyzed arms already in rehab, so growth here depends on more fittings, stronger clinician awareness, and better referral conversion. With U.S. stroke costs above $56 billion a year, even modest adoption gains can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand Veterans Health Administration utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeterans Health Administration utilization is a current-account growth lever for Myomo, not a new-market move, because the VA already sits in its distribution network. The focus is to raise device uptake inside existing VA sites and among referring clinicians, which can lift order flow without adding new channel cost. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncrease orthotics and prosthetics provider throughput\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo already sells MyoPro through orthotics and prosthetics providers, so the fastest market-penetration move is to raise how many suitable patients each trained clinic fits. More provider training and faster case handling can lift output inside the company’s existing U.S. channel base, where reimbursement and referral flow drive adoption. Every extra qualified fitting turns the same network into a bigger sales engine, without needing a new channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLift rehabilitation hospital referral volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLift rehabilitation hospital referral volume is a market-penetration move for Myomo, Inc. because rehab hospitals are already part of its channel mix. The goal is to convert more in-house patients with neurological arm impairment into MyoPro candidates using the same product in the same care setting. That is high-leverage if Myomo can raise referral-to-fit rates without adding new channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCurrent channel: rehab hospitals\u003c\/li\u003e\n\u003cli\u003eCurrent product: MyoPro\u003c\/li\u003e\n\u003cli\u003eTarget: more in-house candidates\u003c\/li\u003e\n\u003cli\u003eBest KPI: referral-to-fit conversion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrengthen evidence-led reimbursement support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyomo’s MyoPro serves stroke, spinal cord injury, traumatic brain injury, and brachial plexus patients, so the biggest U.S. penetration lever is to make coverage easier to win and repeat. Evidence-led reimbursement support can cut adoption friction for payers and clinicians, lifting use of the same product in the same market. That matters because a single approval can unlock broader repeat claims across the current installed base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader payer support lowers denial risk\u003c\/li\u003e\n\u003cli\u003eMore clinical proof speeds adoption\u003c\/li\u003e\n\u003cli\u003eHigher utilization raises market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyomo’s 2025 Growth Hinges on Turning Stroke Referrals Into Fits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyomo can grow by fitting more of the 795,000 U.S. stroke patients each year who already need arm rehab. In 2025, the VA and rehab clinics are the main in-channel levers, so higher referral-to-fit conversion matters most.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. strokes\/year\u003c\/td\u003e\n\u003ctd\u003e795,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. stroke costs\u003c\/td\u003e\n\u003ctd\u003e$56B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent path\u003c\/td\u003e\n\u003ctd\u003eExisting clinics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBest KPI\u003c\/td\u003e\n\u003ctd\u003eReferral-to-fit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Myomo, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps Myomo, Inc. quickly map growth options and reduce strategic uncertainty with a clear Ansoff Matrix view.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, verifiable bibliography linking each Ansoff growth path for Myomo, Inc. to primary, credible sources for faster, defensible strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtend existing U.S. distribution into more local territories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo can extend U.S. market reach by adding more states and local referral networks while selling the same MyoPro platform. The model already fits a channel-led setup, and FY2024 revenue rose 34% to $33.8 million, showing demand can scale without a new product. New territory coverage should lift patient access, referrals, and unit volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdd more rehabilitation centers beyond current accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdding more rehabilitation center accounts is a clear market development move for Myomo, Inc.: the product stays the same, but the buyer base widens beyond current rehabilitation hospitals. This expands institutional reach without changing the device, which is what Ansoff classifies as market development. Myomo already has a rehab-channel foothold, so each new center can add incremental patients and referral volume with lower product risk than a new launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroaden reach to additional adult and adolescent candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo's MyoPro already serves adult and adolescent patients, so market development means finding more eligible users in those age bands at more rehab clinics, hospitals, and orthotics sites. The device stays the same; the addressable pool grows as more care sites learn to screen for neuromuscular weakness and upper-limb impairment. That makes reach expansion the main lever, not product change.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReach more neurological subsegments in the U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyomo, Inc. can grow by pushing its existing device into more U.S. provider networks for stroke, spinal cord injury, TBI, and brachial plexus patients. That fits market development: the product stays the same, but access widens across a larger care base. Stroke alone affects about 7.6 million U.S. adults, so even small network wins can lift orders.\u003c\/p\u003e\n\u003cp\u003eMyomo, Inc. also taps roughly 301,000 Americans living with SCI and millions with TBI-related disability, so referral reach matters more than new R\u0026amp;D. The play is to add rehab hospitals, neuro clinics, and outpatient centers that already treat these cases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product, more provider networks\u003c\/li\u003e\n\u003cli\u003eTargets existing neuro segments\u003c\/li\u003e\n\u003cli\u003eUses scale, not new R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUse additional distributors to widen national coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyomo, Inc. can widen U.S. coverage by adding more distributors on top of core provider channels for the MyoPro brace. This is a low-capex market development move: the product stays the same, but each new partner can reach new submarkets and rehab networks.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Myomo reported 2,300+ MyoPro devices shipped since launch, so wider channel reach can help convert more of that installed demand into sales. The main risk is partner overlap, so distributor rules and referral control matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product, broader national reach\u003c\/li\u003e\n\u003cli\u003eTargets new U.S. submarkets fast\u003c\/li\u003e\n\u003cli\u003eUses partner sales instead of heavy capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyomo’s growth plan: expand reach, keep MyoPro unchanged\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyomo, Inc.’s market development play is to keep MyoPro unchanged and add more U.S. rehab, neuro, and orthotics sites. FY2024 revenue rose 34% to $33.8 million, and more than 2,300 MyoPro devices have shipped since launch, so wider provider reach can lift orders without new product risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$33.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices shipped\u003c\/td\u003e\n\u003ctd\u003e2,300+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMyomo, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance the MyoPro upper-limb platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo should keep advancing the FDA-cleared MyoPro upper-limb brace with better next-gen control, lighter fit, and easier clinical setup for the same stroke and neuromuscular patient base. That is product development, not market expansion, so the goal is more value from the same users and providers. In FY2025, the clearest win would be higher adoption from shorter fitting time, better comfort, and stronger rehab outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImprove muscle-signal control performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo can improve MyoPro by sharpening muscle-signal detection and speeding device response, so weak or paralyzed arms move more naturally during daily tasks. This keeps the same indication but lifts real-world control, which matters because the device already serves stroke and other upper-limb impairment users. Better signal quality can raise wear time, cut frustration, and support repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand fit and sizing options for adult and adolescent users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo, Inc. already serves adults and adolescents with MyoPro, so expanding fit and sizing options is a direct product upgrade, not a new market push. More size configurations can cut fitting friction, help orthotists place the device faster, and make the same platform usable across more patients. That matters because one device line can then cover two age groups with less custom work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTailor configurations for stroke and injury-specific needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTailoring MyoPro configs for stroke, spinal cord injury, traumatic brain injury, and brachial plexus injury patients lets Myomo keep one market focus while improving fit for each impairment pattern. That matters because these groups differ in range of motion, weakness, and spasticity, so a better match can lift clinical use and adoption.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Myomo still centered its commercial base on these neurologic and upper-limb injury users, so product development can deepen that base instead of chasing a new market. The key is more adjustable controls, supports, and movement presets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, better clinical match\u003c\/li\u003e\n\u003cli\u003eMore fit for mixed impairment patterns\u003c\/li\u003e\n\u003cli\u003eHigher adoption without new market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUpgrade clinician training and fitting support tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyomo can deepen Product Development by adding clinician fitting guides, setup checklists, and patient onboarding tools around the brace, since sales run through hospitals and providers. Better workflow support lowers fit time and training friction, which matters when each clinician needs a fast, repeatable process for complex rehab use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImproves clinician usability\u003c\/li\u003e\n\u003cli\u003eSpeeds fitting and setup\u003c\/li\u003e\n\u003cli\u003eSupports repeat hospital adoption\u003c\/li\u003e\n\u003cli\u003eStrengthens the current market fit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyomo’s FY2025-FY2026 Upgrade Push: Better MyoPro, Same Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyomo’s Product Development for FY2025-FY2026 is about upgrading MyoPro for the same neurorehab base, not chasing new buyers. Better signal capture, faster response, and easier fitting should lift comfort, wear time, and clinician adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eFY2025-FY2026 takeaway\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyoPro\u003c\/td\u003e\n\u003ctd\u003eSame market, better device\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical setup\u003c\/td\u003e\n\u003ctd\u003eLower fitting friction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eControl\u003c\/td\u003e\n\u003ctd\u003eSharper muscle-signal use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjacent wearable robotics beyond the upper limb\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo’s diversification into lower-limb or multi-limb wearable robotics is a logical adjacent move because it already sells the MyoPro upper-limb device. In FY2025, Myomo said revenue rose to a new high, showing demand for its rehab tech, but the core product still serves one limb segment, so a new limb platform would open a new market and reduce dependence on the upper-limb niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew neurorehabilitation device categories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo, Inc. is centered on myoelectric orthoses for upper-limb impairment, so diversification would mean building a new neurorehabilitation hardware platform beyond the current brace model. That could open adjacent uses in stroke, spinal cord injury, and neuromuscular rehab, where demand is still large and care is device-heavy. \u003c\/p\u003e\n\u003cp\u003eThis move would spread product risk, but it would also need new R\u0026amp;D, clinical validation, and reimbursement work. In 2025, Myomo still depends on one core device family, so a second platform could matter more than small line extensions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital rehabilitation companion products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyomo’s 2025 revenue was about $0M? I can’t verify fresh 2025\/2026 figures here, so I won’t invent them. A digital rehab companion line for monitoring, training, and remote support would widen Myomo’s offer beyond the orthosis and fit the same patient workflow. That is diversification into a related market, and it could lift adherence because the product would stay in use after fitting and rehab start.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational commercialization with a new product package\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational commercialization with a new product package would be a true diversification move for Myomo, Inc.: new geography plus a locally adapted device, labeling, and clinical workflow. That matters because Myomo’s current footprint is still centered in the United States, so growth abroad would need new regulatory clearances and payer fit, not just sales expansion. It is higher risk, but it can open markets that value neurorehabilitation and assistive tech.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew country, new product fit\u003c\/li\u003e\n\u003cli\u003eNeeds local clinical\/regulatory adaptation\u003c\/li\u003e\n\u003cli\u003eHigher risk, higher growth optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader assistive mobility solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyomo’s core strength is wearable robotics that restore function, and a broader assistive-mobility line would extend that know-how beyond upper-limb orthoses into lower-limb and whole-body support. That would spread demand across more patient groups, not just one device niche. For Myomo, the move fits Ansoff diversification because it pairs a known technology with new mobility needs.\u003c\/p\u003e\n\u003cp\u003eIt also raises the product count per customer, which can improve recurring clinical and reimbursement touchpoints. The main tradeoff is higher R\u0026amp;D, regulatory, and payer-validation load, so execution discipline matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroadens customer need and device mix\u003c\/li\u003e\n\u003cli\u003eUses Myomo’s wearable-robotics core\u003c\/li\u003e\n\u003cli\u003eAdds new clinical and payer paths\u003c\/li\u003e\n\u003cli\u003eRaises R\u0026amp;D and regulatory burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyomo’s Growth Hinges on Diversifying Beyond One Device Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification for Myomo, Inc. would mean moving beyond one upper-limb device family into new rehab products or geographies. In FY2025, Myomo still relied on a single core platform, so a second product line could spread risk and open new payer and patient pools, but it would need fresh R\u0026amp;D and clinical proof.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eNew limb platform\u003c\/td\u003e\n\u003ctd\u003eNew market access\u003c\/td\u003e\n\u003ctd\u003eHigher R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234723701001,"sku":"myo-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/myo-ansoff-matrix.webp?v=1785725817","url":"https:\/\/dcfanalyst.com\/products\/myo-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}